Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05587764 · ClinicalTrials.gov registry record

Tempus Pro Monitor Registry

A clinical trial, sponsored by Philips Clinical & Medical Affairs Global.

Completed
Registry status
103
Enrollment target

NCT05587764: Completed study, sponsored by Philips Clinical & Medical Affairs Global.

NCT05587764 is a clinical trial that has completed, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05587764 has completed, sponsored by Philips Clinical & Medical Affairs Global.

COMPLETED
Registry status
103 participants
Enrollment target

Study Summary

A multicenter, prospective and retrospective, observational, post market study.

Primary Outcome

The proportion of 12-lead ECG pairs that are identical, after a cardiologist's review of printouts from Corsium IntelliSpace (transmitted) ECG and the original ECG from the Tempus Pro device.

Interventions

  • DIAGNOSTIC_TEST Standard of Care

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2024-04-25
Est. Completion 2024-08-12

What the finished NCT05587764 record still lists

NCT05587764 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Standard of Care is the first listed.

NCT05587764 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05587764 about?

NCT05587764 is a clinical study titled "Tempus Pro Monitor Registry". A multicenter, prospective and retrospective, observational, post market study.

What is the current status of trial NCT05587764?

This trial is currently completed. The enrollment target is 103 participants. The study started on 2024-04-25. Estimated completion is 2024-08-12.

What interventions are being tested in trial NCT05587764?

The interventions under investigation include: Standard of Care (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05587764?

This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05587764, the US trial registry maintained by the National Library of Medicine. NCT05587764 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.